Indchemie’s Baddi Manufacturing Facility stands as a benchmark of pharmaceutical excellence, catering to diverse therapeutic needs with its high-capacity production units. Spanning multiple specialized manufacturing blocks, this facility ensures precision, compliance, and efficiency in every formulation.

General Block

The General Block is a versatile production unit equipped for various dosage forms, with an impressive annual capacity of:

• Ointments – 1 Cr unit

• Capsules – 180 Cr units

• Tablets – 30 Cr units

• Liquid formulations – 50 Cr litres (divided into Line 1 and Line 2, Line 1 producing 30 Cr litres and Line 2 producing 20 Cr litres)

Betalactam Block

Dedicated to beta-lactam antibiotics, this specialized block ensures the highest quality standards for penicillin-based drugs, with annual production capacities of:

• Amoxi+Clav Tablets – 20 Cr units

• Amoxi+Clav DS (100 ml syrup) – 1.5 Cr bottles

• Amoxi Tablets – 5 Cr units

• Amoxi Capsules – 150 Cr units

Cepha Block

Focused on cephalosporin antibiotics, this block supports essential formulations with a production capacity of:

• Tablets – 20 Cr units

• Dry Syrup (DS) – 1.5 Cr units

The Baddi plant is a fully GMP-compliant facility equipped with advanced manufacturing technologies and stringent quality control systems, ensuring global regulatory adherence. It plays a crucial role in supplying high-quality pharmaceutical products across domestic and international markets.